New immunotherapy studies for people with advanced melanoma

April 02, 2018

More than 10 studies of investigational and FDA-approved immunotherapies for people with advanced melanoma are currently open at Providence Cancer Institute, including two new studies:

A Phase I Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients with Advanced Solid Tumors

This is a first-in-human study of AEB1102 in patients with advanced cancers. The study is open to patients with cutaneous melanoma, and to patients with small cell lung cancer.

A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined With Nivolumab Versus Nivolumab in Participants With Metastatic or Unresectable Melanoma That is Previously Untreated

The purpose of this study is to find out whether combining BMS-986205 with nivolumab is more effective than nivolumab alone for treating melanoma that has spread or is unable to be removed by surgery, and that has not been treated previously.

For more information or to refer patients to these new studies, please call Providence Cancer Institute’s Clinical Research office at 503-215-2614.

See all open melanoma studies.

See all Providence studies in all cancer types.

Leaders in melanoma research and treatment

Providence Cancer Institute has been an international leader in melanoma research and treatment for more than 20 years. Some highlights of our program and contributions:

  • Providence Cancer Institute researchers led the international study leading to FDA approval of ipilimumab (Yervoy), the first immunotherapy to show a survival benefit in advanced melanoma.
  • Providence also participated in clinical trials leading to FDA approval of the PD-1/PD-L1-blocking antibodies pembrolizumab and nivolumab (Keytruda and Opdivo), which offer improved response and survival benefits as second- or third-line therapies for patients with metastatic melanoma.
  • Providence is one of the top five high-dose Interleukin-2 centers in the country and is an innovator in the use of IL-2 in conjunction with high-dose per fraction radiation.
  • Providence is one of the few melanoma centers offering tumor infiltrating lymphocyte (TIL) therapy in combination with IL-2.

Learn more about the Providence Cancer Institute.